Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2019–2023

ARCH · AGE-RELATED CHANGES IN HEMATOPOIESIS

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2019-06-01 → 2023-11-30
Финансиране от ЕС
3 969 936 €
Участници
19
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Промените в кръвотворенето с възрастта се анализират чрез проучване на заболявания като анемии и левкемии. Това помага да се разберат причините за появата на тези проблеми в различни възрастови групи и начините за забавяне на развитието им.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

AGE-RELATED CHANGES IN HEMATOPOIESIS

An estimated 80 millions people are currently affected by blood disorders in Europe. The clinical management of hematological diseases represents for the European Healthcare a serious medical challenge and an important socio-economical burden, which is expected to increase in the next few years, because of the increased longevity of the European population. Even more important, hematological disorders have a high impact on the quality of life of patients and their families. Ageing is associated with an increased risk of acquiring various blood disorders, either malignant (myelodysplastic syndromes, myeloma, lymphomas) or non-malignant (such as anemias, primary immunodeficiency and coagulation disorders). Other blood disorders occur most often in children and are different from those seen in adults. The different incidence of different blood disorders at different ages suggests that they might reflect and undergo, in their onset and evolution, age-related changes in hematopoiesis, in a largely unknown manner. Many crucial questions remain unanswered. How does blood composition change as we age? Do these physiological changes have an impact on hematological diseases? The answer to these questions was the main focus of ARCH (Age-Related Changes in Hematopoiesis), whose ultimate goal was the characterization of key factors that trigger hematological diseases in distinct age groups and the identification of strategies for delaying or preventing their onset. The effort in this direction was made possible by putting together a network of 15groups from 10 Countries working on different -yet complementary- aspects of hematopoiesis, belonging to both academic and private sectors. The rich portfolio of expertise and its collaborative sharing within the network allowed to develop specific cellular and in vivo models, experimental approaches based on cutting edge technologies including transcriptomics, functional genomics and epigenetics. The above challenges require a multidisciplinary approach that can be tackled only by scientists able to deal with this level of complexity. ARCH enrolled 15 young researchers from 7 countries. Through the development of their research projects, ARCH students challenged themselves in the solving of complex scientific and technical problems. Their parallel training in complementary skills, dealing with the social and ethical implication of biomedical research, further enriched their scientific and personal growth. We believe that ARCH students will contribute fruitfully to European research, economy and society.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз